Chinese TaTME Registry Collaborative

Summary

Total mesorectal excision (TME) is the gold standard procedure for treating rectal cancer. However, in patients with obesity, prostate hypertrophy, low located tumor or/and pelvic stenosis, the traditional laparoscopic or open surgery is not easy to conduct. Transanal total mesorectal excision (TaTME) might serve as a better procedure for these patients, for it might ease the dissection of the low mesorectum. So far, several studies have showed the promising results of TaTME, but the multi-center data in China is still lacking. This nationwide registry study included more than 30 Chinese hospitals, aiming at obtaining data on the safety and efficacy of this procedure in Chinese patients with rectal cancer and encouraging future research in this field.

Conditions

• Rectal Cancer

Sponsors & Collaborators

• Ruijin Hospital

  collaborator OTHER

• Peking Union Medical College Hospital

  collaborator OTHER

• Peking University Cancer Hospital & Institute

  collaborator OTHER

• The First Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• Shengjing Hospital

  collaborator OTHER

• Huashan Hospital

  collaborator OTHER

• Guangdong Dongguan Kanghua Hospital

  collaborator UNKNOWN

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• Nanchong Central Hospital

  collaborator OTHER_GOV

• Sino-Japanese Friendship Hospital of Jilin University

  collaborator UNKNOWN

• Koo Foundation Sun Yat-Sen Cancer Center

  collaborator OTHER

• Shangdong Linzi District People's Hospital

  collaborator UNKNOWN

• Peking University People's Hospital

  collaborator OTHER

• Nantong University

  collaborator OTHER

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• The First Hospital of Jilin University

  collaborator OTHER

• Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

  collaborator OTHER

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• Nanjing PLA General Hospital

  collaborator OTHER

• The First Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• The First Affiliated Hospital of Xiamen University

  collaborator OTHER

• Sichuang Zigong First People's Hospital

  collaborator UNKNOWN

• Beijing Chao Yang Hospital

  collaborator OTHER

• Peking University Third Hospital

  collaborator OTHER

• Jinhua Central Hospital

  collaborator OTHER

• Beijing Hospital

  collaborator OTHER_GOV

• The First Affiliated Hospital of Zhengzhou University

  collaborator OTHER

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• LanZhou University

  collaborator OTHER

• Chinese PLA General Hospital

  collaborator OTHER

• Cancer Hospital of Guizhou Province

  collaborator OTHER

• First Hospital of China Medical University

  collaborator OTHER

• First Affiliated Hospital of Chongqing Medical University

  collaborator OTHER

• Beijing Friendship Hospital

  lead OTHER

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-11-15

Primary Completion

2018-11-15

Completion

2021-11-15

Countries

• China

Study Locations